secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2021-08-20T23:59:59+00:00
Accession:  0001625101-21-000044
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences appoints Mitchell E. Levinson as Chief Strategy Officer
-------------------------------------------------------------------------

- Appointment effective August 19, 2021; Levinson continues as board member.
- He brings 30+ years in med device, co-founded Cerebrotech and was early Zeltiq employee.
- Role is newly created; company plans multi-specialty expansion using CellFX platform.
- No financial guidance or earnings changes announced in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000162510121000044/0001625101-21-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000162510121000044/plse-20210819x8k.htm
  HTML page:      https://secwatch.observer/filing/0001625101-21-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer